← 홈

ADC · 흑색종

9개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 9개
ADCCBiologicEli Lilly and CompanyPhase 2

Abemaciclib (Abemaciclib)

Advanced Cancer; Metastatic Melanoma · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 32.9%임상시험 77상태 RECRUITING
ADCBiologicMedImmune LLCPhase 2

Dabrafenib (Dabrafenib)

Melanoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 100%임상시험 69상태 DISCONTINUED
ADCBiologicAmerican Society of Clinical On…Phase 2

Dabrafenib plus Trametinib (Dabrafenib plus Trametinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 57상태 RECRUITING
ADCBiologicstaleMerckPhase 2

nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab))

Melanoma · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 38%임상시험 31상태 DISCONTINUED
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING
ADCBiologicstaleCelldex TherapeuticsPreclinical

glembatumumab vedotin (glembatumumab vedotin)

Metastatic gpNMB Expressing Triple Negative Breast Cancer · Melanoma

#Melanoma#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 21%임상시험 9상태 ACTIVE
ADCBiologicstaleHummingbird BiosciencePhase 2

ENV-501 (ENV-501)

Melanoma (Skin); Non Small Cell Lung Cancer · Melanoma (Skin)

#MelanomaSkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and CDX-301 (glembatumumab vedotin and CDX-301)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 7%임상시험 1상태 DISCONTINUED
ADCBiologicstaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and varlilumab (glembatumumab vedotin and varlilumab)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 7%임상시험 1상태 DISCONTINUED